Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

PubMed  Google Scholar 

Prostate cancer statistics. Cancer Research UK https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer (updated 23 April 2026).

Carm, K. T. et al. Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer. Sci. Rep. 9, 13579 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Haffner, M. C. et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat. Rev. Urol. 18, 79–92 (2021).

Article  PubMed  Google Scholar 

Parker, C. et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1119–1134 (2020).

Article  CAS  PubMed  Google Scholar 

EAU Guidelines Office. Uroweb — European Association of Urology http://uroweb.org/guidelines/compilations-of-all-guidelines (2026).

Schaeffer, E. M. et al. NCCN guidelines® insights: prostate cancer, version 1.2023. J. Natl Compr. Canc. Netw. 20, 1288–1298 (2022).

PubMed  Google Scholar 

Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Primers 7, 9 (2021).

Article  PubMed  Google Scholar 

Sandhu, S. et al. Prostate cancer. Lancet 398, 1075–1090 (2021).

Article  CAS  PubMed  Google Scholar 

Roy, S. & Morgan, S. C. Who dies from prostate cancer? An analysis of the surveillance, epidemiology and end results database. Clin. Oncol. 31, 630–636 (2019).

Article  CAS  Google Scholar 

Hieronymus, H. et al. Copy number alteration burden predicts prostate cancer relapse. Proc. Natl Acad. Sci. USA 111, 11139–11144 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cancer Genome Atlas Research Network The molecular taxonomy of primary prostate cancer. Cell 163, 1011–10135 (2015).

Article  Google Scholar 

Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).

Article  CAS  PubMed  Google Scholar 

Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177–188 (2008).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Magi-Galluzzi, C. et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71, 489–497 (2011).

Article  CAS  PubMed  Google Scholar 

Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93–99 (2020).

Article  CAS  PubMed  Google Scholar 

Ren, S. et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur. Urol. 73, 322–339 (2018).

Article  CAS  PubMed  Google Scholar 

Dong, B. et al. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun. Biol. 3, 778 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jaratlerdsiri, W. et al. African-specific molecular taxonomy of prostate cancer. Nature 609, 552–559 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong, T. et al. Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers. Genome Med. 14, 100 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu, J. et al. Spatially resolved transcriptomic analysis of the adult human prostate. Nat. Genet. 57, 922–933 (2025).

Article  CAS  PubMed  Google Scholar 

Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun, J. et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67, 692–700 (2007).

Article  CAS  PubMed  Google Scholar 

Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 162, 454 (2015).

Article  CAS  PubMed  Google Scholar 

Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230–3238 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 130, 1743–1751 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369–378 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mikutenaite, M. et al. Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer. Nat. Commun. 16, 11338 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoury, J. D. et al. Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial. Clin. Cancer Res. 24, 521–531 (2018).

Article  CAS  PubMed  Google Scholar 

Isaacsson Velho, P. et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur. Urol. 77, 14–21 (2020).

Article  CAS  PubMed  Google Scholar 

Schaeffer, E. M. et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 21, 1067–1096 (2023).

Article